Preview

V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY

Advanced search

Stratification of the risk of developing tardive drug-induced complications

Full Text:

Abstract

Tardive drug dystonia / dyskinesia is one of the rare, and at the same time, the most severe motor complications associated with the use of pharmacological drugs. Complex assessment of risk factors for the development of tardive drug-induced side effects makes it possible to take a more rational approach for the target therapy, to make rehabilitation more effective and safe.

About the Authors

L. A. Khublarova
V.M. Bekhterev national research medical center for psychiatry and neurology
Russian Federation


D. V. Zakharov
V.M. Bekhterev national research medical center for psychiatry and neurology
Russian Federation


V. A. Mikhaylov
V.M. Bekhterev national research medical center for psychiatry and neurology
Russian Federation


References

1. Бойко А.С. Клинико-биологические особенности тардивной дискинезии у больных шизофренией на фоне длительной антипсихотической терапи. Диссертация на соискание ученой степени кандидата медицинских наук. - 2016. - 2016. - С. 38-40.

2. Ветохина Т.Н. Кандидатская диссертация «Особенности клинических проявления и течения экстрапирамидных синдромов, вызванных приемом нейролептиков». - М. - 2006. - С. 124.

3. Корнетова Е.Г., Семке А.В., Дмитриева Е.Г., Бородюк Ю.Н., Бойко А.С Клинические и социальные факторы риска тардивной дискинезии у пациентов с шизофренией в процессе лечения антипсихотиками. - Бюллетень сибирской медицины. - 2015. - Т.14. - С. 32-39.

4. Насырова РФ., Иванов М.В., Незнанов Н.Г. Введение в психофармакогенетику. Монография. - СПб. - 2015. - С. 48-94.

5. Шток В.Н., Иванова-Смоленская И.А., Левин О.С. Экстрапирамидные расстройства. Руководство по диагностике и лечению. - М., МЕДпресс - информ. - 2002. - С. 99-103.

6. Chakos M. Shirakawa O. Lieberman J.A. et al. Striatal enlargement in rats chronically treated with neuroleptic. - Biol Psyhiatry - 1998. - Vol. 44. - P. 665-684.

7. Chen C.H., Wei F.C., Koong F.J., Hsiao K.J. Association of Taq1 A polymorphism of dopamine D2-receptor gene and tardive dyskinesia in schizophrenia. - Biol Psyhiat. -1997. - P. 827-829.

8. Chong S.A., Sachdev P.S. eds Пє epidemiology of tardive dyskinesia. - NY Marcel Dekker. - 2004. - P. 318-320.

9. Delay J, Deniker P. 1957; Schonecker M. Paroxysmal dyskinesia as the effect of megaphen. - Nervenarzt. -1957. - Vol. 28. - P. 550-553.

10. DeLeon M. and Jankovic J. «Clinical features and management of classic tardive dyskinesia, tardive myoclonus, tardive tremor and tourettism» in K.D. Sethi Drug induced movement disorders. - New York. - 2004. - P. 77-109.

11. Faubrye A., Rash P.J. Petersen P.D. et al. Neurological Symptoms in Pharmacotherapy of Psyhoses. - Acta Psyhiatr Scand. - 1964. - P. 10-27.

12. Ganzini L., Heintz R.T., Hoffman R.F., Casey D.E. The prevalence of tardive dyskinesia in neuroleptic - treated diabetics A controlled study. - Arch gen psychiatric. - 1991. - P. 259-263.

13. Gunasekara N.S. Quetiapine. A Review of its Use in Schizophrenia / N.S. Gunasekara, C.M. Spencer // CNS Drugs. -1998. - V.9. - P. 325-340.

14. Jankovic J. Tardive syndromes and other drug-induced movement disorders // Clin. Neuropharmacol. -1995. - P. 11-14.

15. Jensvold M.F., Halbreich U., Hamilton J.A. Psychopharmacology and Women: Sex, Gender, and Hormones. Washington, DC: American Psychiatric Press. -1996. - P. 18-19.

16. Jeste D.V., Caliguri M.P. Tardive dyskinesia. - Shizophr Bull. - Vol. 19. - P. 303-315.

17. Jeste D.V. Wyatt R.J. Prevention and management of tardive dyskinesia. - J clin Psyhiatry. -1985. - Vol. 46. - P. 14-18.

18. Kane J.M., Smith J.M. Tardive dyskinesia: prevalence and risk factors 1959 to 1979. - Arch Gen Psyhiat. -1982. - P. 473-481.

19. Klawans H.L. Recognition and diagnosis of tardive dyskinesia // J. Clin. Psychiatry. - 1985. - Vol. 46, № 4. - P. 3-7.

20. Khot V., Egan M.F., Hyde T.M., Wyatt R.J. Neuroleptics and classic tardive dyskinesia/ In A.E. Lang, W.J. Weirner. Drug-induced movement disorders. - Mt Kisco: Futura. - 1992. - P. 121-166.

21. Lerner V., Kaptsan A., MiodownikC. etal. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study //Clin. Neuropharmacol.-1999. - Vol. 22. - P. 241-243.

22. Meats, P. Quetiapine (Seroquel): an effective and well-tolerated atypical antipsychotic / P. Meats // Int. J. Psychiatry in Clinical Practice. - 1997. - V 1. - P. 231-239.

23. Mena M.A., Yebenes J.G. Drug induced parkinsonism»/ - 2006. - P.201-202.

24. Mentzel C.L., Tenback D.E., Tijssen M.A., Visser - Vindewalle VE van Harten PM. Efficacy and safety of deep brain stimulation in patients with medication-induced tadive dyskinesia and/or dystonia : a systematic review. - J Clin Psyhiatry. - 2012. - Vol. 73. - P. 1434-1438.

25. Morgan J.C., Harrison M.B. Antiepileptics. In: Factor S.E., Lang A.E., Weiner W.J., editors. Drug induced movement disorders. 2nd ed. - Maiden: Blackwell Futura. - 2005. - P. 408-429.

26. Nausieda P.A., Koller W.C., Weiner W.J., Klawans H.L. Chorea induced by oral contraceptives. - Neurology. -1979. - Vol. 29. - P. 1605-1609.

27. Nguyen N., Pradel V., Micallef J., Montastruc J.L., Blin O.L. «Drug induced Parkinson syndromes». - Therapie. - 2004. - P. 185-196.

28. Segman R.H., Lerer B. Age and relationship of dopamine D3, serotonin 2c and serotonin 2a receptors genes to abnormal involuntary movements in chronic schizophrenia. - Mol Psyhiatr. - 2002. - P. 137-139.

29. Shedlack K.J. et al. Rapidly prodressive tardive dyskinesia in AIDS. - Biol Psychiatry. - 1994. - Vol. 35. - P. 147-148.

30. Shyamal H. Mehta Kapil D. Sethi Drug induced movement disorders. Movement disorders in neurological and systematic disease. - Cambridge medicine. - 2014. - P. 203-220.

31. Streen V.M. Lovilie R. MacEwan T. McCreadie R.G. Dopamine D3 receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. - Mol Pssyhiat. - 1997. - P. 139-145.

32. Thobois S., Xie J., Mollion H., Benatru I., Broussolle E. Adrafinil-induced orofacial dyskinesia. - Mov Disord. - 2004. - Vol.19. - P. 965-966. Greil W., Haag H., Rossnagl G., Riither E. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. - Br J Psychiatry. - 1984. - Vol. 145. - P. 304-310.

33. Woerner M.G., Alvir J.M. Saltz B.M. et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. - Am J Psyhiatri. - 1998. - Vol. 155. - P. 1521-1528.

34. Woerner MG Kane JL Weinhold P. Incidence of tardive dyskinesia: five year data from a prospective study. - Psychofarmacological Bull. - 1984. - P. 87-89.

35. Woerner M.G., Saltz B.L., Kane J.L. Diabetes and development of tardive dyskinesia. - Am J psiychiat. -1993. - P. 966-968.

36. Woogen S., Graham J., Angrist B. «A tardive dyskinesia-like syndrome after amitriptyline treatment.» - J Clin Psychopharmacol. - 1981. - Vol.1. - P. 34-36.

37. Xiang, Y.T. Tardive dyskinesia in the treatment of schizophrenia: the findings of the Research on Asian Psychotropic Prescription Pattern (REAP) survey. - 2001-2009. - P. 382-387.

38. Yonkers K.A., Hamilton J.A. Psychotropic medications. In: Oldham J.M., Riba M.B., eds. Review/of Psychiatry. - Washington, DC: American Psychiatric Press. -1995. - Vol. 14. - P. 307-332.


For citation:


Khublarova L.A., Zakharov D.V., Mikhaylov V.A. Stratification of the risk of developing tardive drug-induced complications. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2017;(4):111-114. (In Russ.)

Views: 356


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2313-7053 (Print)